File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: A randomized, double-blind, placebo-controlled trial of abciximab for prevention of in-stent restenosis in diabetic patients after coronary stenting: results of the ASIAD (Abciximab in Stenting Inhibits restenosis Among Diabetics) Trial

TitleA randomized, double-blind, placebo-controlled trial of abciximab for prevention of in-stent restenosis in diabetic patients after coronary stenting: results of the ASIAD (Abciximab in Stenting Inhibits restenosis Among Diabetics) Trial
Authors
Issue Date2005
PublisherHMP Communications, LLC. The Journal's web site is located at http://www.invasivecardiology.com/jic/index.cfm
Citation
Journal of Invasive Cardiology, 2005, v. 17 n. 10, p. 534-538 How to Cite?
AbstractOBJECTIVES: Coronary stenting is associated with a high incidence of restenosis in patients with diabetes mellitus. Recent data suggest that diabetic patients treated with abciximab have a lower rate of target vessel revascularization (TVR). We sought to investigate whether abciximab can reduce in-stent restenosis after coronary stenting in diabetic patients. METHODS: In this prospective double-blind trial, we randomly assigned 254 patients with type 2 diabetes mellitus undergoing nonurgent coronary stenting to receive abciximab with an initial heparin bolus of 50 U/kg (n = 128) or placebo with an initial heparin bolus of 70 U/kg (n = 126). All patients received aspirin and clopidogrel before the procedure. The primary endpoint was angiographic restenosis by quantitative coronary angiography at 6 months. The secondary endpoint was death, myocardial infarction (MI), or target lesion revascularization (TLR) at 6 months. RESULTS: The clinical, angiographic, and procedural characteristics were matched between the 2 groups. Angiographic follow-up was completed in 226 patients (90%). Angiographic restenosis occurred in 29.1% of the abciximab group, and 24% of the placebo group (p = 0.30). The rates of the secondary endpoint were similar between the 2 groups (23.4% in the abciximab group versus 22.2% in the placebo group; p = 0.88). TLR was performed on 36 (18.4%) lesions in 29 (23.4%) patients of the abciximab group, and 26 (13.6%) lesions in 23 (18.3%) patients of the placebo groups, respectively (p = 0.21 and 0.35, respectively). CONCLUSIONS: Abciximab does not reduce angiographic restenosis or TLR in type 2 diabetic patients undergoing nonurgent coronary stenting.
Persistent Identifierhttp://hdl.handle.net/10722/163014
ISSN

 

DC FieldValueLanguage
dc.contributor.authorChen, WHen_HK
dc.contributor.authorKaul, Uen_HK
dc.contributor.authorLeung, SKen_HK
dc.contributor.authorLau, YKen_HK
dc.contributor.authorTan, HCen_HK
dc.contributor.authorLeung, AWen_HK
dc.contributor.authorLee, MKen_HK
dc.contributor.authorLi, SKen_HK
dc.contributor.authorNg, Wen_HK
dc.contributor.authorLee, PYen_HK
dc.contributor.authorLam, KFen_HK
dc.contributor.authorTse, HFen_HK
dc.contributor.authorLau, CPen_HK
dc.date.accessioned2012-09-05T05:26:33Z-
dc.date.available2012-09-05T05:26:33Z-
dc.date.issued2005en_HK
dc.identifier.citationJournal of Invasive Cardiology, 2005, v. 17 n. 10, p. 534-538en_HK
dc.identifier.issn1557-2501en_HK
dc.identifier.urihttp://hdl.handle.net/10722/163014-
dc.description.abstractOBJECTIVES: Coronary stenting is associated with a high incidence of restenosis in patients with diabetes mellitus. Recent data suggest that diabetic patients treated with abciximab have a lower rate of target vessel revascularization (TVR). We sought to investigate whether abciximab can reduce in-stent restenosis after coronary stenting in diabetic patients. METHODS: In this prospective double-blind trial, we randomly assigned 254 patients with type 2 diabetes mellitus undergoing nonurgent coronary stenting to receive abciximab with an initial heparin bolus of 50 U/kg (n = 128) or placebo with an initial heparin bolus of 70 U/kg (n = 126). All patients received aspirin and clopidogrel before the procedure. The primary endpoint was angiographic restenosis by quantitative coronary angiography at 6 months. The secondary endpoint was death, myocardial infarction (MI), or target lesion revascularization (TLR) at 6 months. RESULTS: The clinical, angiographic, and procedural characteristics were matched between the 2 groups. Angiographic follow-up was completed in 226 patients (90%). Angiographic restenosis occurred in 29.1% of the abciximab group, and 24% of the placebo group (p = 0.30). The rates of the secondary endpoint were similar between the 2 groups (23.4% in the abciximab group versus 22.2% in the placebo group; p = 0.88). TLR was performed on 36 (18.4%) lesions in 29 (23.4%) patients of the abciximab group, and 26 (13.6%) lesions in 23 (18.3%) patients of the placebo groups, respectively (p = 0.21 and 0.35, respectively). CONCLUSIONS: Abciximab does not reduce angiographic restenosis or TLR in type 2 diabetic patients undergoing nonurgent coronary stenting.en_HK
dc.languageengen_US
dc.publisherHMP Communications, LLC. The Journal's web site is located at http://www.invasivecardiology.com/jic/index.cfm-
dc.relation.ispartofThe Journal of invasive cardiologyen_HK
dc.subject.meshAntibodies, Monoclonal - Therapeutic Useen_US
dc.subject.meshAspirin - Therapeutic Useen_US
dc.subject.meshBlood Coagulation - Drug Effectsen_US
dc.subject.meshCoronary Angiography - Methodsen_US
dc.subject.meshCoronary Disease - Etiology - Therapyen_US
dc.subject.meshCoronary Restenosis - Prevention & Controlen_US
dc.subject.meshDiabetes Mellitus, Type 2 - Complicationsen_US
dc.subject.meshDouble-Blind Methoden_US
dc.subject.meshFemaleen_US
dc.subject.meshFollow-Up Studiesen_US
dc.subject.meshHumansen_US
dc.subject.meshImmunoglobulin Fab Fragments - Therapeutic Useen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshPlatelet Aggregation Inhibitors - Therapeutic Useen_US
dc.subject.meshPlatelet Glycoprotein Gpiib-Iiia Complex - Antagonists & Inhibitorsen_US
dc.subject.meshProspective Studiesen_US
dc.subject.meshStentsen_US
dc.subject.meshTiclopidine - Analogs & Derivatives - Therapeutic Useen_US
dc.titleA randomized, double-blind, placebo-controlled trial of abciximab for prevention of in-stent restenosis in diabetic patients after coronary stenting: results of the ASIAD (Abciximab in Stenting Inhibits restenosis Among Diabetics) Trialen_HK
dc.typeArticleen_HK
dc.identifier.emailLam, KF: hrntlkf@hkucc.hku.hken_HK
dc.identifier.emailTse, HF: hftse@hkucc.hku.hken_HK
dc.identifier.emailLau, CP: cplau@hku.hk-
dc.identifier.authorityLam, KF=rp00718en_HK
dc.identifier.authorityTse, HF=rp00428en_HK
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.pmid16204748-
dc.identifier.scopuseid_2-s2.0-33748107700en_HK
dc.identifier.hkuros114988-
dc.identifier.volume17en_HK
dc.identifier.issue10en_HK
dc.identifier.spage534en_HK
dc.identifier.epage538en_HK
dc.identifier.scopusauthoridChen, WH=7409637978en_HK
dc.identifier.scopusauthoridKaul, U=7102340294en_HK
dc.identifier.scopusauthoridLeung, SK=7202044902en_HK
dc.identifier.scopusauthoridLau, YK=7201403303en_HK
dc.identifier.scopusauthoridTan, HC=7403011676en_HK
dc.identifier.scopusauthoridLeung, AW=7403012697en_HK
dc.identifier.scopusauthoridLee, MK=35278417600en_HK
dc.identifier.scopusauthoridLi, SK=8270281600en_HK
dc.identifier.scopusauthoridNg, W=7401613562en_HK
dc.identifier.scopusauthoridLee, PY=8933949600en_HK
dc.identifier.scopusauthoridLam, KF=8948421200en_HK
dc.identifier.scopusauthoridTse, HF=7006070805en_HK
dc.identifier.scopusauthoridLau, CP=7401968501en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats